PX91.F Cassava Sciences Inc

Healthcare Biotechnology Frankfurt Exchange
0.4165 EUR
Close of Nov 13, 2026
0.3955 2.99
Market cap
EUR 20.9M
P/E
-
P/B
0.41x
ROE
-68.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PX91.F undervalued?

Graham number

The Graham number of Cassava Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cassava Sciences Inc fundamental analysis

No fundamental analysis for Cassava Sciences Inc yet.

Cassava Sciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cassava Sciences Inc

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, In…

Full company profile